Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Site Study to Evaluate the Irritation and Sensitization Potential of Repeat Applications of Rotigotine Transdermal System, 1 mg/24 hr Versus Neupro (Rotigotine Transdermal System), 1 mg/24 hr in Healthy Volunteers

NCT02727205 is registered in ClinicalTrials.gov with Inflamax Research Incorporated as lead sponsor.

NCT NCT02727205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02727205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Site Study to Evaluate the Irritation and Sensitization Potential of Repeat Applications of Rotigotine Transdermal System, 1 mg/24 hr Versus Neupro (Rotigotine Transdermal System), 1 mg/24 hr in Healthy Volunteers
Lead sponsor
Inflamax Research Incorporated
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
October 31, 2013
Enrollment
260 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalence - irritation and sensitization potential of transdermal patch